Virtual Library

Start Your Search

Saugata Sen

Author of

  • +

    P1.12 - Small Cell Lung Cancer/NET (Not CME Accredited Session) (ID 944)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P1.12-19 - Clinico-Pathological Characteristics and Treatment Outcome in Small Cell Lung Cancer: A Single Institutional Experience (ID 11314)

      16:45 - 18:00  |  Author(s): Saugata Sen

      • Abstract
      • Slides


      Lung cancer is one of the commonest cancer in the world with a high rate of mortality. Small cell lung cancer constitutes around 14% of all lung cancers. Literature on small cell lung cancer is scarce in literature. The aim of the study was to analyze clinical profile of patients with lung cancer and their treatment outcome.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      This is a single institutional data review of patients treated between June 2011 and Dec 2017 with diagnosis of small cell carcinoma of lung. Patients were staged as either localized or extensive disease after appropriate staging work-up. Patients with localized disease were treated with concurrent chemo-radiation with platinum based chemotherapy. Those with extensive disease were treated with platinum based palliative chemotherapy. Clinic-pathological characteristics, treatment details and outcome were recorded in this study. Response assessment was done using RECIST criteria wherever applicable. Patients who received at least 1 cycle of palliative chemotherapy were included for survival analysis.

      4c3880bb027f159e801041b1021e88e8 Result

      Total 128 patients were registered with median age of 62 years (range: 38-86), male:female ratio of 115:13. The ECOG performance status was 0 in 2, 1 in 30 (23%), 2 in 64, (50%) 3 in 29 (22%) and 4 in 3 patients. Ninety-percent (n=112) patients had smoking history and 20% (n=25) patients had symptom of superior vena cava obstruction at baseline. Eleven (9%) patients had localized disease at presentation. Sixteen (12.5%) patients had brain metastasis at presentation. Eighty-two (64%) patients took palliative chemotherapy and eight (10%) of them had localized disease. Chemotherapy regimen was – carboplatin only in 5 (6%), etoposide-carboplatin in 29 (35%) and cisplatin-etoposide in 48 (58%). Patients received median cycle number of 6 (range:1-6). Of the evaluable 58 (71%) patients, initial response was complete response in 2, partial response in 37, stable disease in 15 and progressive disease in 4. Fifteen patients received second-line chemotherapy on progression of disease. After a median follow-up of 6.7months (range: 0.3 - 36.6), median progression-free survival was 8.6 months.. After a median follow up of 12.5 months (range:0.3-36.6), median overall survival was 8.7 months.

      8eea62084ca7e541d918e823422bd82e Conclusion

      Small cell carcinoma in our series had high incidence of advanced stage (91%) and 10% patients were non- smoker. Only 64% patients received palliative chemotherapy and achieved high disease control rate (>90%) in the evaluable patients with median progression-free survival of 8.6 months and median overall survival of 8.7 months.


      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.